Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health
- Publication Type:
- Journal Article
- Value in Health, 2019, 22 (5), pp. 593 - 600
- Issue Date:
|Health Technology Assessment challenges in oncology 20 years of value in health.pdf||Published Version||656.94 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
© 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research Background: Oncology treatments have changed from chemotherapies to targeted therapies and more recently immuno-oncology. This has posed special challenges in the field of health technology assessment (HTA): capturing quality of life (QOL) associated with toxicity due to chemotherapy, crossover upon progression in targeted therapy trials, and survival extrapolation for immuno-oncology drugs. Objectives: To showcase 20 years of Value in Health (ViH) publications in oncology. Methods: A review was undertaken of oncology articles published in ViH from May 1998 to August 2018. Full-length articles published in ViH with the keywords “oncology,” “cancer,” “h(a)ematology,” and “malignancy” were included for review. Conference abstracts were excluded. Results: Four major themes were identified: (1) QOL and the development of multiple functional assessment of cancer therapy tools and mapping instruments; (2) analysis of clinical evidence using indirect comparisons, network analyses, and adjustment for crossovers; (3) modeling, Markov models, partitioned survival models, and extrapolation methods; and (4) financial implications and how to deal with uncertainty, introduction of conditional reimbursement, managed entry, and risk share agreements. Discussion: This review article highlights the important role ViH has played in disseminating HTA research in oncology. A few key issues loom on the horizon: precision medicine, further development and practical application of new QOL measures, methods for translating clinical evidence, and exploration of modeling techniques. For a better understanding of the complex interplay between access and financial risk management, ViH will no doubt continue to promote pioneering research in HTA and oncology.
Please use this identifier to cite or link to this item: